Impact of Conversion From Advagraf to Twice-Daily Generic Tacrolimus in Kidney Transplant Recipients: A Single-Center Study—A 3-Year Follow-Up
We included patients with stable renal function, serum creatinine less than 2.0 mg/dL, transplanted for 6 months or longer. Tacrolimus conversion was performed on a 1 mg:1 mg basis. Thereafter, doses were adjusted to maintain target trough levels between 5 and 10 ng/mL. Our main endpoints were patient and graft survival at 12, 24, and 36 months. Secondary endpoints included evolution of serum creatinine levels 36 months after conversion and biopsy-proven acute rejection episodes.
From the 109 included patients, there were 99 active on tacrolimus at 36 months. Graft and patient survival was 100% at 12- and 24-month follow-up. At 36 months, death-censored graft survival was 93% and patient survival was 97%. There were 3 deaths with a functioning graft, 1 infectious, 1 neoplastic, and 1 cardiovascular, and 4 patients were transferred to hemodialysis due to chronic allograft dysfunction. Two patients transited to cyclosporine, for diabetes and posterior reversible encephalopathy syndrome, and 1 to sirolimus due to Kaposi syndrome. The serum creatinine levels were not statistically different at conversion and 36 months follow-up (P = 0.737). There were no episodes of acute rejection. Doses were statistically different between conversion and 3 months (P < 0.001) and between 3 and 36 months (P < 0.001). Trough levels were not statistically different at conversion and 3 months (P = 0.595) but were between 3 and 36 months (P < 0.001) (Table 1).
In our study, the twice-daily generic formulation proved to be safe, with serum creatinine levels stable at conversion and at 36 months follow-up. The patients that transited to hemodialysis had been transplanted 10 years previously and were probably on a process of chronic allograft dysfunction at conversion. One third of our patients needed dose reduction at 14 days or 1 month after conversion to avoid toxicity, meaning that conversion was not on a strict 1 mg:1 mg basis in all patients, as suggested. On the other hand, this represented a great increase in the number of outpatient visits.3 Statistically significant differences between tacrolimus doses and levels at 3-month and 36-month follow-up probably reflect a clinical tendency to lower trough levels of tacrolimus in renal transplantation that influenced our practice (trough tacrolimus levels 3-7 ng/mL).4,5 Additionally, our study was limited by the small sample size, and the fact that it is a single-center study.
In conclusion, the twice-daily generic tacrolimus seems to provide similar efficacy and safety to Advagraf at 36-month follow-up. Additional drug monitoring postconversion should be recommended because 1 of every 3 patients may require dose titration to avoid toxicity.